Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (141-150 of 224) with videos related to

Pageof 23
Sort By:
Oncology Letters|November 14, 2025
Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM studyAlexandre Harlé, Céline Gavoille, Olivier Bouché, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2016
Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic CellsJeanne Galaine, Guillaume Kellermann, Yves Guillaume, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumorMagalie Dosset, Yann Godet, Charline Vauchy, et al.
Breast Cancer Research : BCR|February 7, 2025
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruptionMorgane Lopez, Laurie Spehner, Fabrice André, et al.
World Journal of Gastrointestinal Oncology|March 25, 2020
FOLFOXIRI <i>vs</i> FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort studyAngélique Vienot, Hortense Chevalier, Clément Bolognini, et al.
Clinical Pharmacokinetics|June 18, 2016
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer PatientsMorgane Caulet, Thierry Lecomte, Olivier Bouché, et al.
Nature Communications|May 6, 2021
PPARɣ drives IL-33-dependent ILC2 pro-tumoral functionsGiuseppe Ercolano, Alejandra Gomez-Cadena, Nina Dumauthioz, et al.
BMC Cancer|October 27, 2016
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric studyChristelle d'Engremont, Dewi Vernerey, Anne-Laure Pointet, et al.
Oncoimmunology|January 23, 2025
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgerySyrine Abdeljaoued, Alexandre Doussot, Marie Kroemer, et al.
Molecular Oncology|December 26, 2021
Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort studyMarine Jary, Wen-Wei Liu, Dongyao Yan, et al.
Pageof 23

Showing results (141-150 of 224) with videos related to

Sort By:
Pageof 23
Oncology Letters|November 14, 2025
Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM studyAlexandre Harlé, Céline Gavoille, Olivier Bouché, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2016
Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic CellsJeanne Galaine, Guillaume Kellermann, Yves Guillaume, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumorMagalie Dosset, Yann Godet, Charline Vauchy, et al.
Breast Cancer Research : BCR|February 7, 2025
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruptionMorgane Lopez, Laurie Spehner, Fabrice André, et al.
World Journal of Gastrointestinal Oncology|March 25, 2020
FOLFOXIRI <i>vs</i> FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort studyAngélique Vienot, Hortense Chevalier, Clément Bolognini, et al.
Clinical Pharmacokinetics|June 18, 2016
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer PatientsMorgane Caulet, Thierry Lecomte, Olivier Bouché, et al.
Nature Communications|May 6, 2021
PPARɣ drives IL-33-dependent ILC2 pro-tumoral functionsGiuseppe Ercolano, Alejandra Gomez-Cadena, Nina Dumauthioz, et al.
BMC Cancer|October 27, 2016
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric studyChristelle d'Engremont, Dewi Vernerey, Anne-Laure Pointet, et al.
Oncoimmunology|January 23, 2025
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgerySyrine Abdeljaoued, Alexandre Doussot, Marie Kroemer, et al.
Molecular Oncology|December 26, 2021
Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort studyMarine Jary, Wen-Wei Liu, Dongyao Yan, et al.
Pageof 23